Carlos Zagoya

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score

Jochen G. Mainz, Carlos Zagoya, Louise Polte et al. · Frontiers in Pharmacology · 2022 · 85 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study

Jochen G. Mainz, Karen Lester, B. Elnazir et al. · Journal of Cystic Fibrosis · 2023 · 39 citations

Medicine, Clinical Sciences, Pharmacotherapy +13

Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid

Jochen G. Mainz, Christin Arnold, Kara Wittstock et al. · Frontiers in Immunology · 2021 · 33 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis

L.R. Caley, Carlos Zagoya, Franziska Duckstein et al. · Journal of Cystic Fibrosis · 2023 · 15 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Diagnosing constipation in patients with cystic fibrosis applying ESPGHAN criteria

Marina A. Stefano, Natascha Silva Sandy, Carlos Zagoya et al. · Journal of Cystic Fibrosis · 2021 · 12 citations

Medicine, Clinical Sciences, Internal Medicine +7